BioSpace News Archive

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis’ presentation has been scheduled for Wednesday, October 2, 2019 at 8:55 AM EDT / 5:55 AM PDT.

The National Council on Disability released the first of five reports in a bioethics and disability series and calls on the U.S. Department of Health and Human Services Office for Civil Rights and the U.S. Department of Justice to issue critical federal guidance on organ transplant discrimination.

RedRick Technologies, a provider of purpose-built ergonomic workstations for professionals, monitor mounting solutions and reading room design guidance, will be exhibiting at the upcoming Digital Pathology Association’s Annual Meeting in Orlando, Florida from October 18 - 20.

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), today reported Validations of System Performance for their X-Series® products from two prestigious academic medical centers:

Healogics®, the nation’s wound expert, today announced that it has appointed Rob Doll to serve as Chief Marketing Officer.

Stryker announced today the publication of the SAKOS pivotal trial results for the SpineJack implantable fracture reduction system (SpineJack System) in The Spine Journal

This evening, American Skin Association (ASA) was awarded a $10,000 Community Grant from The Allergan Foundation at a celebratory reception held for grant recipients at the Allergan U.S. Administrative Headquarters.

Palo Alto Health Sciences, Inc. (PAHS), whose product Freespira® is the only FDA-cleared digital therapeutic for treating panic attacks, panic related disorders, and PTSD is pleased to announce the addition of Joseph (Joe) Perekupka to its Senior Executive team as Chief Commercial Officer

Working with state partners, FDA and CDC have been investigating an outbreak of severe lung injury associated with the use of vaping products.